These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37084815)

  • 1. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System.
    Grella CE; Ostile E; Scott CK; Dennis M; Carnavale J
    Int J Drug Policy; 2020 Jul; 81():102768. PubMed ID: 32446130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
    Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
    Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions.
    Rockett ML; Knudsen HK; Oser CB
    J Subst Use Addict Treat; 2024 Jul; 162():209353. PubMed ID: 38521351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
    Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
    Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
    [No Abstract]   [Full Text] [Related]  

  • 10. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 and treating incarcerated populations for opioid use disorder.
    Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
    J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for opioid addiction in community corrections.
    Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
    Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
    Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
    Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.